Protein kinase Cα-mediated chemotaxis of neutrophils requires NF-κB activity but is independent of TNFα signaling in mouse skin in vivo

被引:61
作者
Cataisson, C
Pearson, AJ
Torgerson, S
Nedospasov, SA
Yuspa, SH
机构
[1] NCI, Ctr Canc Res, Lab Cellular Carcinogenesis & Tumor Promot, Bethesda, MD 20892 USA
[2] SAIC, Basic Res Program, Ft Detrick, MD 21702 USA
[3] NCI, Canc Res Ctr, Mol Immunoregulat Lab, Frederick, MD 21701 USA
关键词
D O I
10.4049/jimmunol.174.3.1686
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Protein kinase C (PKC) isoforms are major regulators of cutaneous homeostasis and mediate inflammation in response to 12-O-tetradecanoylphorbol-13-acetate (TPA). We have previously reported that transgenic mice overexpressing PKCalpha in the skin exhibit severe intraepidermal neutrophilic inflammation and keratinocyte apoptosis when treated topically with TPA. Activation of PKCalpha increases the production of TNFalpha and the transcription of chemotactic factors (MIP-2, KC, S100A8/A9), vascular endothelial growth factor, and GM-CSF in K5-PKCalpha keratinocytes. In response to PKCalpha activation, NF-kappaB translocates to the nucleus and this is associated with IkappaB phosphorylation and degradation. Preventing IkappaB degradation reduces both the expression of inflammation-associated genes and chemoattractant release. To determine whether TNFalpha mediated NF-kappaB translocation and subsequent expression of proinflammatory factors, K5-PKCalpha mice were treated systemically with a dimeric soluble form of p75 TNFR (etanercept) or crossed with mice deficient for both TNFR isoforms, and keratinocytes were cultured in the presence of TNFalpha-neutralizing Abs. The in vivo treatment and TNFR deficiency did not prevent inflammation, and the in vitro treatment did not prevent NF-kappaB nuclear translocation after TPA. Together these results implicate PKCa as a regulator of a subset of cutaneous cytokines and chemokines responsible for intraepidermal inflammation independent of TNFalpha. PKCalpha inhibition may have therapeutic benefit in some human inflammatory skin disorders.
引用
收藏
页码:1686 / 1692
页数:7
相关论文
共 56 条
[1]   Targeted mutation of TNF receptor I rescues the ReIA-deficient mouse and reveals a critical role for NF-κB in leukocyte recruitment [J].
Alcamo, E ;
Mizgerd, JP ;
Horwitz, BH ;
Bronson, R ;
Beg, AA ;
Scott, M ;
Doerschuk, CM ;
Hynes, RO ;
Baltimore, D .
JOURNAL OF IMMUNOLOGY, 2001, 167 (03) :1592-1600
[2]   Expression of both TNF-α receptor subtypes is essential for optimal skin tumour development [J].
Arnott, CH ;
Scott, KA ;
Moore, RJ ;
Robinson, SC ;
Thompson, RG ;
Balkwill, FR .
ONCOGENE, 2004, 23 (10) :1902-1910
[3]   CONSTITUTIVE NF-KAPPA-B ACTIVATION, ENHANCED GRANULOPOIESIS, AND NEONATAL LETHALITY IN I-KAPPA-B-ALPHA-DEFICIENT MICE [J].
BEG, AA ;
SHA, WC ;
BRONSON, RT ;
BALTIMORE, D .
GENES & DEVELOPMENT, 1995, 9 (22) :2736-2746
[4]  
Blauvelt Andrew, 2003, Journal of Allergy and Clinical Immunology, V111, pS560
[5]   MEASUREMENT OF CUTANEOUS INFLAMMATION - ESTIMATION OF NEUTROPHIL CONTENT WITH AN ENZYME MARKER [J].
BRADLEY, PP ;
PRIEBAT, DA ;
CHRISTENSEN, RD ;
ROTHSTEIN, G .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1982, 78 (03) :206-209
[6]   S100 protein subcellular localization during epidermal differentiation and psoriasis [J].
Broome, AM ;
Ryan, D ;
Eckert, RL .
JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY, 2003, 51 (05) :675-685
[7]   Activation of cutaneous protein kinase Cα induces keratinocyte apoptosis and intraepidermal inflammation by independent signaling pathways [J].
Cataisson, C ;
Joseloff, E ;
Murillas, R ;
Wang, A ;
Atwell, C ;
Torgerson, S ;
Gerdes, M ;
Subleski, J ;
Gao, JL ;
Murphy, PM ;
Wiltrout, RH ;
Vinson, C ;
Yuspa, SH .
JOURNAL OF IMMUNOLOGY, 2003, 171 (05) :2703-2713
[8]   CACHEXIA AND GRAFT-VS-HOST-DISEASE-TYPE SKIN CHANGES IN KERATIN PROMOTER-DRIVEN TNF-ALPHA TRANSGENIC MICE [J].
CHENG, J ;
TURKSEN, K ;
YU, QC ;
SCHREIBER, H ;
TENG, M ;
FUCHS, E .
GENES & DEVELOPMENT, 1992, 6 (08) :1444-1456
[9]   Immune functions of the skin [J].
Debenedictis, C ;
Joubeh, S ;
Zhang, GY ;
Barria, M ;
Ghohestani, RF .
CLINICS IN DERMATOLOGY, 2001, 19 (05) :573-585
[10]  
DLUGOSZ AA, 1995, METHOD ENZYMOL, V254, P3